INDIGO Now Offering LRH-1 Assay Systems

State College, PA (January 20, 2016)-INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded its offerings to include liver homology receptor-1 (LRH-1) kits and services.

LRH-1, also called NR5A2, is a nuclear receptor that is an essential regulator of gene transcription, critical for early cellular development and imperative for the proper functions of the liver, pancreas, and intestines during the adult life. In the liver, LRH-1 regulates the expression of key genes involved in bile acid synthesis, cholesterol homeostasis and transport. Because of its decisive role in cell differentiation, LRH-1 is linked to multiple developmental pathways. LRH-1 activity is linked to breast and endometrial cancers as well as intestinal tumors and cancer of the pancreas.

Due to these critical roles of this receptor in human physiology, LRH-1 continues to be a promising target for drug discovery. “We are excited to add LRH-1 to our portfolio. It represents a significant expansion in drug discovery capabilities for those interested for cholesterol homeostasis and certain cancers. LRH-1 enhances our industry leading position in nuclear receptor research” says Dr. Jack Vanden Heuvel, Chief Scientific Officer.

INDIGO’s LRH-1 assay kits are cell-based genetic reporter assay systems. The assay kits are all-inclusive systems, including optimized media for use during cell culture and in preparing test compound treatments, a LRH-1 reference agonist, luciferase detection reagents, and an assay plate.